At OriGen, we take great pride in providing products to customers, distributors, and end users for use in critical cell therapy processes to save live...
Read More
Chimeric antigen receptor (CAR) T-cell therapy is a type of regenerative immunotherapy developed to aid in treating various blood cancers. CAR-T thera...
Read More
The story of OriGen Biomedical began in 1990 when Richard Martin, our founder, and Bo Johnson, our cofounder, received FDA approval for our first prod...
Read More
AUSTIN, September 2022: OriGen Biomedical, Inc., a leading producer of cryopreservation, cell culture, and respiratory products, has unveiled updated ...
Read More
Since 2010, every September is recognized as Blood Cancer Awareness Month, a month intended to shed light on the cancers that affect the blood and lym...
Read More
This year, OriGen is celebrating 25 years of success in the cell therapy and respiratory industries. OriGen was founded in 1997 and has grown into a w...
Read More
Please note: This product has been discontinued and we are not accepting POs. Current therapies for bronchoalveolar lavage (BAL) for foreign matter ...
Read More
AUSTIN, August 2022: OriGen Biomedical, Inc., a leading producer of cryopreservation, cell culture, and respiratory products, is pleased to announce t...
Read More
AUSTIN, August 2022: OriGen Biomedical, Inc., a leading producer of cryopreservation, cell culture, and respiratory products, announced today that the...
Read More
Institutional processes, protocols, and operational needs can differ substantially from one organization to the next. To alleviate this, OriGen priori...
Read More